H.U. Group Holdings,Inc. Q3 FY2025 earnings call

• Overall Consolidated Performance

  • 2024 1-3Q cumulative results delivered 4.5 billion yen revenue growth, 3.8 billion yen growth in both EBITDA and operating profit year-over-year, representing an increase in both revenue and profit. EBITDA margin reached 9.9%, supporting solid operating cash flow generation.
  • A 2.82 billion yen distribution from a 2017 venture fund investment was recorded as capital gains, offsetting 260 million yen in prior operating losses. After including this gain and foreign exchange gains, plus smaller equity method investment losses following withdrawal from China's testing service business, ordinary profit grew sharply to ~4.3 billion yen, and net profit reached ~2.8 billion yen.
  • Operating cash flow increased 3.7 billion yen year-over-year, driven by higher EBITDA and reduced net working capital. Free cash flow also increased year-over-year despite higher investment cash outflow from an earn-out payment to Fluxus. Net interest-bearing debt remained stable at prior period levels.

• Capital Project Progress

  • The H.U. Bioness Complex system relocation remains on schedule: reporting systems have already been transferred, and the final sales/billing/collection system transfer is on track to complete by the end of March 2025, with full operation starting in April 2025. One-time costs and depreciation are expected to come in lower than original guidance, reducing the current fiscal year P/L impact.

• Profitability Initiatives

  • Contribution margin improvement initiatives are progressing as planned. While fixed cost reduction has been delayed, the initiatives have already delivered some benefits that contributed to full year profit growth.

1. LTS Segment: Excluding COVID-19 related revenue, the base business (including genetic testing) grew 7% year-over-year, with total test volume increasing 6% year-over-year. The segment delivered year-over-year profit growth driven by higher revenue, gradual benefits from profitability improvement initiatives, and lower one-time H.U. Bioness Complex relocation costs compared to the prior year. Operating losses continued into the 3rd quarter. 2. IVD Segment: Base business (driven by strong growth of Neuro reagents for Lumipulse overseas) remained solid, but overall revenue decreased year-over-year due to lower COVID-19 related sales. While higher overseas R&D investment for ultra-sensitive detection technology and Neuro growth, plus lower COVID-19 revenue reduced profit, the segment maintained a operating margin above 20% and an EBITDA margin of ~30%. 3. HS Segment: Sterilization-related business performed solidly, delivering year-over-year revenue growth. The segment achieved year-over-year profit growth due to profitability improvements and the absence of the one-time costs that impacted the prior year period.

• Full-year 2024 consolidated revenue guidance is maintained, as offsetting changes across segments cancel out any net change.
• EBITDA and operating profit full-year guidance is revised downward by 5.5 billion yen. The downward revision is driven by delayed fixed cost reduction benefit realization in the LTS segment, and higher-than-planned overseas R&D costs (including foreign exchange impacts) in the IVD segment that will lead to full-year IVD results coming in slightly below plan.
• The downward revision to ordinary profit is smaller than the revision to operating profit, as the venture fund distribution gain was already recorded in the 3rd quarter. Net profit is also revised downward following the ordinary profit adjustment.
• The 3rd quarter saw quarter-on-quarter profit growth, and management expects this trend to continue, resulting in quarter-on-quarter profit growth in the 4th quarter.
• The planned dividend per share is unchanged from the initial forecast, and management will maintain a stable dividend for shareholder returns.
• Management reaffirms that the medium-term target of 10%+ operating margin remains unchanged, and no downward adjustment to the 5-year target plan is planned.

• Fixed cost reduction initiatives (covering personnel costs, maintenance costs, and outsourcing expenses across all business areas) in the LTS segment have progressed slower than initially planned, with cost reduction falling short of 3rd quarter targets. This slowdown is a continuation of a trend that has persisted through the year, not a sudden new development.
• Recent industry-wide changes have negatively impacted the overall profitability of the LTS business, and the company has not yet completed the organizational restructuring needed to adapt to this new environment, particularly for personnel and outsourcing costs which are significantly below planned reduction targets.
• Delays to the H.U. Bioness Complex full startup schedule have had a minor negative impact on overall fixed cost reduction progress.
• IVD segment R&D costs for growth initiatives are coming in higher than initial plans, partially driven by unfavorable foreign exchange movements that increase the yen-denominated cost of overseas R&D.
• Seasonal factors and potential epidemic-related demand shifts (such as reduced patient visits during influenza/COVID-19 surges) are uncertainty factors for 4th quarter performance, though these risks are already incorporated into the revised guidance.

Q: What specific factors are behind the delayed fixed cost reduction in LTS that drove the current downward revision, given the H.U. Bioness Complex schedule change was announced 3 months prior? Is this delay a sudden new issue or a reflection of ongoing underperformance that is now being incorporated into guidance? / A: Fixed cost reduction (across personnel, maintenance, outsourcing and all other areas) is behind plan in the 3rd quarter, and the slowdown has been an ongoing trend all year, not a sudden new development. The H.U. Bioness Complex startup delay has also added a minor incremental impact to overall fixed cost reduction, so all factors are combined under the description of delayed fixed cost reduction effect. After updating the full-year outlook to the end of March 2025, management determined a downward revision was necessary. (376 characters)

Q: Why is IVD guiding to higher overseas R&D costs for the full year when year-to-date R&D costs are lower than last year? What explains the gap between initial plan and current forecast, including foreign exchange and other factors? / A: The higher planned R&D cost is for the 4th quarter, reflecting proactive planned investment in ultra-sensitive detection technology and Neuro reagent growth. Initial guidance assumed an exchange rate of 140 yen per USD, and current unfavorable yen depreciation has increased the yen-denominated cost of this overseas investment. Management incorporated this expected 4th quarter cost increase into the revised full-year guidance, which matches the questioner's understanding of higher Q4 R&D spending for these initiatives. (402 characters)

Q: Revised guidance shows quarter-on-quarter profit growth from Q3 to Q4, which is unusual given historical Q4 seasonal profit weakness. What is the background for this expectation, and is improvement in profitability expected over this period? / A: The company typically budgets a higher proportion of full-year profit in the second half. While the revised guidance expects Q4 profit to be lower than the initial plan, LTS performance has gradually improved quarter-over-quarter from Q1 to Q3 this year. Even with the downward revision, Q4 is still expected to be profitable compared to average historical Q4 results, delivering quarter-on-quarter profit growth from Q3, just below the original budget target. (351 characters)

Q: Does the delayed profitability improvement in LTS change the medium-term 10%+ operating margin target, or will the company be able to catch up next year? Does this delay push the target out by 1-2 years? / A: The current year delay is mostly driven by the H.U. Bioness Complex startup delay. The medium-term plan already includes all the strategic initiatives for future growth (including H.U. Bioness Complex and CDMO), and next fiscal year will enter the phase of harvesting benefits from these already planted initiatives. Management does not believe a large downward adjustment to the original medium-term targets is necessary, and will work to deliver on the original 5-year plan goals. (362 characters)